Sotorasib plus panitumumab may be a promising treatment option for colorectal cancer
1. While not statistically significant, the use of sotorasib plus panitumumab may have a 30% relative risk reduction in the...
Oncology
Reports of high-impact oncology studies by medical professionals
Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism
1. Recurrent VTE occurred in 2.1% in the reduced-dose group and 2.8% in the full-dose group, with HR 0.76 (was...
Genetic, clinical, lifestyle and sociodemographic risk factors for head and neck cancer:
1. The highest-ranking phenotypic predictors of head and neck cancer included past tobacco smoking, job code at baseline, pain experienced...
Imlunestrant extends progression-free survival in ER-positive, HER2-negative breast cancer
1. In this randomized controlled trial, in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced...
![Fluorophores enhance visualization for image-guided surgery [PreClinical]](https://www.2minutemedicine.com/wp-content/uploads/2015/01/FISH_13_21-350x250.jpg)
Taletrectinib in ROS1 mutated Non–Small Cell Lung Cancer
1 .The objective response rate was 88.8% for TKI-naïve patients and 55.8% for TKI-pretreated patients. 2. Most common adverse events...
Nivolumab plus ipilimumab improves progression-free survival in metastatic colorectal cancer
1. Progression-free survival was significantly greater in the nivolumab plus ipilimumab group compared to nivolumab alone. 2. Treatment-related adverse events...
Less frequent mammography is non-inferior to annual screening for breast cancer survival in women after curative treatment
1. 5-year breast cancer-specific survival was comparable between annual and less frequent mammography groups. 2. Less-frequent mammographic surveillance showed a...
Low-Dose CT for Lung Cancer Screening in a High-Risk Population
1. A total of 2% of the eligible population was diagnosed with lung cancer after a positive screen on baseline...
Active Surveillance vs Standard Surgery Post-Neoadjuvant Chemoradiotherapy for Esophageal Cancer
1. Overall survival at 2 years was 74% for active surveillance and 71% for standard surgery. 2. Median disease-free survival...
Venetoclax plus azacitidine demonstrating efficacy for high-risk myelodysplastic syndromes
1. In patients with treatment-naive high-risk myelodysplastic syndromes (HR MDS), the use of venetoclax (14 days) plus azacitidine was well...